Tim Gardner, Ph.D., Riffyn

Tim Gardner, Ph.D. Timothy Gardner is the Founder and the CEO of Riffyn. He was previously Vice President of Research & Development at Amyris, where he led the engineering of yeast strain and processes technology for large-scale bio-manufacturing of renewable chemicals. Earlier, he was an Assistant Professor of Biomedical Engineering at Boston University, the Founder of Cellicon Biotechnologies, and a Programmer at ALK Associates. Tim has been recognized for his pioneering work in Synthetic Biology by Scientific American, the New Scientist, Nature, Technology Review, and the New York Times. He also served as an advisor to the European Union Scientific Committees and the Boston University Engineering Alumni Advisory Board. He holds BS in Mechanical Engineering from Princeton University and a PhD in Biomedical Engineering from Boston University.

Session

4:25 PM - 5:00 PM

Innovation Spotlight Changemaker Presentations

The Innovation Spotlight Presentation program features six changemaker speakers along with moderator Travis McCready, President & CEO of Massachusetts Life Sciences Center. Each speaker presents a concise and fast-paced 5-minute presentation that will introduce you to an innovative way of solving a problem, a new technology or tool, or a transformative approach to solving common issues facing biopharma companies today. Immediately following the spotlight presentations, attendees can meet with these innovative companies in a relaxed atmosphere during the evening reception.

Moderator

Changemaker Presenters

  • Ijah Mondesire-Crump, MD

    Ijah Mondesire-Crump, MD Director of Clinical Research nQ Medical, Inc.

    • Organizations must recognize barriers to adoption of digital health. Proprietary devices and task-based apps are inversely proportional to patient adoption.
    • Target “people” and not just patients.
    • Digital health products must be built on tomorrow’s healthcare system, not today’s.

 

  • Kyle Martin Flickinger

    Kyle Martin Flickinger Vice President Bio Pharmaceutical Solution Strategy Deep Lens

    • Speed to Hope – What does confirmation of diagnosis in precision oncology really imply?
    • The use of digital pathology case management workflow and AI to support clinical research as a care option:
        – What is the need? What are the solutions? Where is Digital pathology heading?

     

  • Tim Gardner, Ph.D.

    Tim Gardner, Ph.D. Founder/CEO Riffyn

    Lab data to machine learning in 30 seconds

    • Lab challenge: data heterogeneity, silos, constant change in R&D
    • Data challenge: systems lack structure, flexibility, accessibility
    • Solution: evolvable “scientific blueprints”: bridge silos with clean & connected data
  • David Wild, Ph.D.

    David Wild, Ph.D. Founder & President Data2Discovery Inc

    • Data2Discovery is applying AI in drug discovery and decreasing the process from 6 years to 6 weeks!
    • By using target identification methods and a disease-driven approach to find new therapies, the cost it takes to bring a drug to market is significantly reduced.
    • David will discuss Use Case examples which address: 1) the business problem of finding new leads as quickly as possible for an ROI, and 2) how the importance of understanding the disease and the intricate biological
      relationships in the data is crucial.


Download Latest Agenda